PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors

PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors

Patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a poor overall prognosis despite chemotherapy and radiotherapy (e.g., peptide receptor radionuclide therapy (PRRT)). Better treatment options are needed to improve disease regression and patient survival. The p...

Full description

Bibliographic Details
Main Authors: Zeta Chow, Jeremy Johnson, Aman Chauhan, Tadahide Izumi, Michael Cavnar, Heidi Weiss, Courtney M. Townsend, Lowell Anthony, Carrigan Wasilchenko, Matthew L. Melton, Jörg Schrader, B. Mark Evers, Piotr Rychahou
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cells
Subjects:
neuroendocrine tumor
radiosensitization
PI3K inhibitor
Online Access:https://www.mdpi.com/2073-4409/10/5/1261

Internet

https://www.mdpi.com/2073-4409/10/5/1261

Similar Items